The interaction between thymic epithelial tumors (TETs) and myasthenia gravis (MG) represents a fascinating and ... potential long-term risks associated with the surgical removal of thymus (4). In ...

An enhanced CT scan of the thymus showed a mass-like soft tissue density in the ... Consensus Guidance for Management (5), the final diagnosis was MG with Myasthenia Gravis Foundation of America (MGFA ...

To determine if myasthenia gravis (MG) with antibodies to MuSK is a distinct subgroup of seronegative MG. Methods: We assayed antibodies to muscle specific tyrosine kinase (MuSK) in 55 MG patients who ...

Thymoma is an uncommon epithelial tumour originating from the thymus gland, having an incidence of 0.13 ... frequently present with paraneoplastic diseases, especially myasthenia gravis, whereas ...

The Vivacity-MG3 study is currently in its open-label extension phase, which is investigating the longer-term safety and ...

For part 3 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the favorable safety and efficacy profile of nipocalimab for generalized myasthenia gravis (gMG).

It’s show-me time for batoclimab, an antibody treatment from Immunovant and Roivant Sciences. Here's what you need to know.

Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular disorder myasthenia gravis.

Belgian biopharma UCB has been given the green light by the FDA for Zilbrysq as a treatment for generalised myasthenia gravis (gMG), one of two drugs that the company hopes will shake up the ...

“Our discovery—the regulatory T cell recirculation back to the thymus—promotes repair through a process that hasn’t been described before and represents a novel pathway to regeneration ...

The team’s study results, published today in the journal Immunity, outline their discovery of a specific type of regulatory T cell that can home back into the thymus and repair the organ when it ...